How India Exports Omeprazole to the World

Omeprazole has been extensively approved in the United States through Abbreviated New Drug Applications (ANDAs). For instance, Sun Pharmaceutical Industries Limited received approval for ANDA 207891 on May 30, 2018, for Omeprazole Delayed-Release Tablets, 20 mg (OTC). This approval granted Sun Pharmaceutical 180 days of generic drug exclusivity, commencing from the date of commercial marketing.

The regulatory pathway for Omeprazole in the U.S. involves demonstrating bioequivalence to the reference listed drug, as outlined in the FDA's Orange Book. Given the presence of 975 active Indian exporters and a buyer count of 2,858, with a repeat buyer rate of 59.0%, the competitive landscape underscores the importance of strict adherence to FDA regulations to maintain market access.

In the European Union, Omeprazole is subject to marketing authorization by the European Medicines Agency (EMA). A notable example is the approval of Omeprazole TriviumVet, a veterinary medicinal product, on April 15, 2025. (ema.europa.eu) The EMA's Committee for Medicinal Products for Human Use (CHMP) has also conducted referrals to harmonize product information across member states, as seen with the Losec (omeprazole) referral concluded on June 10, 2010. (ema.europa.eu)

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and monitoring of Omeprazole products. For instance, on June 30, 2025, the MHRA issued a Class 3 Medicines Recall for Omeprazole 20 mg/15 ml Oral Solution by Glenmark Pharmaceuticals Europe Ltd due to product quality concerns. (gov.uk)

Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers exporting to these regions. The presence of 179 destination countries for Indian Omeprazole exports highlights the necessity for exporters to align with diverse regulatory standards.

Omeprazole is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global health. The drug is also subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards ensures the quality and efficacy of Omeprazole across different markets.

In India, Omeprazole is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing under the Drug Price Control Order (DPCO). As of March 2026, the ceiling price for Omeprazole 20 mg capsules is set at ₹5.00 per capsule. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

The primary patents for Omeprazole have expired, leading to significant generic competition globally. This competitive environment is reflected in the average Free on Board (FOB) unit price of $49.82 for Indian exports. Exporters must navigate this landscape by ensuring compliance with international regulatory standards and maintaining competitive pricing strategies.

In June 2025, the MHRA issued a Class 3 Medicines Recall for Omeprazole 20 mg/15 ml Oral Solution by Glenmark Pharmaceuticals Europe Ltd due to product quality concerns. (gov.uk)

In April 2025, the EMA approved Omeprazole TriviumVet, a veterinary medicinal product, expanding the scope of Omeprazole's applications within the EU market. (ema.europa.eu)

In March 2026, the NPPA revised the ceiling price for Omeprazole 20 mg capsules to ₹5.00 per capsule, impacting pricing strategies for domestic manufacturers and exporters.

In February 2026, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of Omeprazole, highlighting its continued importance in global healthcare.

In January 2026, the CDSCO issued new guidelines for the export of pharmaceutical products, emphasizing the need for stringent quality control measures, directly affecting Omeprazole exporters.

These developments underscore the dynamic regulatory environment surrounding Omeprazole, necessitating continuous monitoring and compliance by exporters to maintain market access and competitiveness.

Omeprazole, a widely used proton pump inhibitor, is primarily manufactured in India, which has established itself as a significant producer of Active Pharmaceutical Ingredients (APIs). However, the production of these APIs is heavily reliant on Key Starting Materials (KSMs) imported from China. This dependency poses a substantial risk, as any disruption in the supply of KSMs can halt API production, leading to shortages of the final pharmaceutical product. According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, highlighting the critical nature of this supply chain vulnerability.

Recent events have underscored this risk. In October 2025, the U.S. Pharmacopeia reported that 58% of KSMs used for U.S.-approved APIs are sole sourced from a single country, with 41% from China and 16% from India. This concentration increases the potential for supply chain disruptions, emphasizing the need for diversification in sourcing strategies.

The export data for Omeprazole from India reveals a high level of supplier concentration. The top five exporters—Sun Pharmaceutical Industries Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd, Micro Labs Limited, and Mylan Laboratories Limited—account for 64.2% of the total export value. Sun Pharmaceutical Industries Limited alone contributes 26.8% of the exports. This concentration indicates a significant single-source risk; any operational or regulatory issues affecting these key suppliers could disrupt the global supply of Omeprazole.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at promoting domestic manufacturing of critical KSMs, Drug Intermediates (DIs), and APIs. As of December 2025, the scheme has led to the creation of manufacturing capacity for 26 KSMs/APIs, resulting in cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore. While this initiative is a positive step towards reducing import dependency, its impact on Omeprazole's supply chain remains to be fully realized.

The global pharmaceutical supply chain is susceptible to geopolitical tensions and shipping disruptions. The Red Sea and the Strait of Hormuz are critical maritime routes for the transportation of pharmaceutical ingredients and finished products. Any instability in these regions can lead to delays and increased costs. Additionally, ongoing U.S.-China trade tensions have the potential to disrupt the supply of KSMs from China, further exacerbating supply chain vulnerabilities.

Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued alerts regarding drug shortages linked to supply chain disruptions. For instance, in February 2025, the FDA issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practice (cGMP), highlighting ongoing quality concerns and the potential for supply interruptions.

• Diversify Sourcing of KSMs and APIs: Engage with multiple suppliers across different regions to reduce dependency on a single source, thereby enhancing supply chain resilience.

• Strengthen Supplier Audits and Quality Controls: Implement rigorous auditing processes to ensure compliance with cGMP standards, minimizing the risk of regulatory actions that could disrupt supply.

• Invest in Domestic Manufacturing Capabilities: Leverage government initiatives like the PLI scheme to develop local production of critical KSMs and APIs, reducing reliance on imports.

• Develop Contingency Plans for Geopolitical Disruptions: Establish alternative shipping routes and maintain strategic stockpiles to mitigate the impact of geopolitical tensions and shipping disruptions.

• Enhance Collaboration with Regulatory Authorities: Maintain open communication with bodies like the FDA and EMA to stay informed about potential regulatory changes and proactively address compliance issues.

RISK_LEVEL: MEDIUM